Stockscreener 앱 받기
1.25
53.37%
0.435
시간 외 거래:
1.08
-0.17
-13.60%
Decoy Therapeutics Inc 주식(DCOY)의 최신 뉴스
Decoy Therapeutics Inc. (DCOY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
DCOY Stock Price and Chart — NASDAQ:DCOY - TradingView — Track All Markets
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - marketscreener.com
Decoy Therapeutics Reaches Global Access Commitment Agreement With Gates Foundation; Stock Up - Nasdaq
Decoy Therapeutics Faces Challenges Amid Market Fluctuations - StocksToTrade
Decoy Therapeutics Faces Major Headwinds Amid Financial Struggles - timothysykes.com
Decoy Therapeutics reaches global access commitment agreement to focus on development of a globally accessible, scalable peptide-conjugate manufacturing platform - marketscreener.com
Decoy Therapeutics Reaches Global Access Commitment Agreement To Focus On Development Of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - TradingView — Track All Markets
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - PR Newswire
Salarius Pharmaceuticals Rebrands as Decoy Therapeutics on Nasdaq - TipRanks
DCOYDecoy Therapeutics Inc Stock Price and Quote - Finviz
Salarius Pharmaceuticals changes name to Decoy Therapeutics - marketscreener.com
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker - Investing.com
Salarius Pharmaceuticals, Inc. Announces Rebranding to Decoy Therapeutics Inc. with Nasdaq Trading Under DCOY Starting January 8, 2026 - Quiver Quantitative
Biotech rebrands as Decoy Therapeutics to pursue next-gen antivirals - Stock Titan
Hanish, director at Salarius, sells shares worth $17 By Investing.com - Investing.com Australia
Hanish, director at Salarius, sells shares worth $17 - Investing.com
Salarius Pharmaceuticals adjourns annual meeting due to low turnout By Investing.com - Investing.com Canada
Decoy Therapeutics pivots to next-gen antivirals for multi-virus threats - Stock Titan
Salarius (Nasdaq: SLRX) teams with Texas Biomed on H5N1 avian flu inhibitor testing - Stock Titan
Salarius Pharma (NASDAQ: SLRX) notes CapIQ errors, has ~$14M cash post Decoy merger - Stock Titan
Salarius Pharmaceuticals clarifies continued Nasdaq listing after merger - Investing.com
Salarius Pharmaceuticals and Decoy Therapeutics Finalize Merger - citybiz
Salarius Pharmaceuticals Upcoming Merger: What to Expect? - timothysykes.com
Salarius Pharmaceuticals, Inc. (SLRX) Stock: Plunges 51% After $7M Public Offering Announcement - parameter.io
Salarius Pharma Stock Jumps After-Hours As Nasdaq Compliance Clears Path For Decoy Merger — Retail Bulls Bet On Breakout - Stocktwits
Salarius Pharmaceuticals amends merger terms, adjusts preferred stock conversion - Investing.com
Salarius Pharmaceuticals Appoints New Acting CEO - TipRanks
Decoding Salarius Pharmaceuticals’ Stock Movement - timothysykes.com
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard - marketscreener.com
SLRXSalarius Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board - marketscreener.com
Decoy Therapeutics’ antiviral candidates show broad activity against multiple viruses - BioWorld MedTech
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses - marketscreener.com
Salarius Pharmaceuticals Advances Merger with Decoy Therapeutics to Enhance Development of Innovative Cancer and Viral Therapeutics - Nasdaq
Shareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders - marketscreener.com
Valerio Therapeutics announces acquisition of Emglev Therapeutics - Pharmaceutical Technology
Salarius: Q2 Earnings Snapshot - marketscreener.com
Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting - marketscreener.com
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split - marketscreener.com
Salarius: Q1 Earnings Snapshot - marketscreener.com
Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses - marketscreener.com
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders - marketscreener.com
Simcha Therapeutics Announces License & Option Agreement to Develop Novel Decoy-resistant IL-18 for Use in Cell Therapy Applications - Business Wire
Salarius: Q3 Earnings Snapshot - marketscreener.com
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources - marketscreener.com
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference - marketscreener.com
Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program - marketscreener.com
Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC - marketscreener.com
Salarius Pharmaceuticals to Present at Virtual H.C. Wainwright BioConnect, Participate in Virtual Biotech Showcase and BIO Partnering @ JPM During "J.P. Morgan Week 2022" - marketscreener.com
SLRX News Today | Why did Salarius Pharmaceuticals stock go up today? $SLRX - MarketBeat
2.73%
2.37%
자본화:
|
볼륨(24시간):